阿兹屈南
肺炎克雷伯菌
微生物学
肉汤微量稀释
阿维巴坦
抗菌剂
棋盘
最小抑制浓度
生物
β-内酰胺酶抑制剂
抗药性
体内
抗生素耐药性
抗菌剂
美罗培南
化学
医学
作者
Jingchun Kong,Zhuocheng Yao,Yanlei Zheng,Jiayi Zhang,Xiaotuan Zhang,Endian Sun,Changrui Qian,Yao Sun,Tieli Zhou
摘要
BACKGROUND: Klebsiella pneumoniae carbapenemase (KPC) mutations are a major mechanism of ceftazidime-avibactam resistance. We aimed to investigate the antimicrobial activity of aztreonam-avibactam against KPC variant-producing K. pneumoniae. METHODS: Antimicrobial susceptibility of 36 KPC variant-producing K. pneumoniae strains was determined by broth microdilution method. The bactericidal kinetic characteristics were analysed by time-kill assays. The interaction between aztreonam and avibactam was analysed by the checkerboard assay and inhibitory Emax model with a baseline effect parameter. blaKPC cloning, molecular docking and enzymatic kinetic analysis was performed to analyse the interactions between KPC variants and substrates. In vivo antibacterial activity was investigated using the Galleria mellonella infection model and the neutropenic mouse intraperitoneal infection model. RESULTS: Aztreonam-avibactam exhibited an MIC50 of 1 mg/L and an MIC90 of 2 mg/L against KPC variant-producing strains, with a rapid bactericidal effect; however, one KPC-14-producing strain showed resistance (8 mg/L). The inhibitory Emax model effectively fitted the observed values from checkerboard assay: aztreonam MICs decreased rapidly as avibactam concentration increased, and gradually reached a plateau. Despite a reduced susceptibility to avibactam inhibition, these KPC variants exhibit impaired aztreonam hydrolysis, with aztreonam MICs decreasing by 2- to 1024-fold relative to KPC-2. In vivo, aztreonam-avibactam significantly increased the survival rate of G. mellonella and reduced the bacterial load in the organs of mice infected with KPC variant-producing K. pneumoniae strain. CONCLUSIONS: Aztreonam-avibactam represents an effective therapeutic option for KPC variant-producing K. pneumoniae.
科研通智能强力驱动
Strongly Powered by AbleSci AI